GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Molecular Transport Inc (NAS:AMTI) » Definitions » ROC (Joel Greenblatt) %

Applied Molecular Transport (Applied Molecular Transport) ROC (Joel Greenblatt) % : -2,140.71% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Applied Molecular Transport ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Applied Molecular Transport's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -2,140.71%.

The historical rank and industry rank for Applied Molecular Transport's ROC (Joel Greenblatt) % or its related term are showing as below:

AMTI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1266.67   Med: -877.35   Max: -257.83
Current: -257.83

During the past 5 years, Applied Molecular Transport's highest ROC (Joel Greenblatt) % was -257.83%. The lowest was -1266.67%. And the median was -877.35%.

AMTI's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -339.53 vs AMTI: -257.83

Applied Molecular Transport's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Applied Molecular Transport ROC (Joel Greenblatt) % Historical Data

The historical data trend for Applied Molecular Transport's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Molecular Transport ROC (Joel Greenblatt) % Chart

Applied Molecular Transport Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
ROC (Joel Greenblatt) %
-1,266.67 -877.35 -1,063.68 -371.65 -289.86

Applied Molecular Transport Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -233.35 -253.56 -203.63 -207.18 -2,140.71

Competitive Comparison of Applied Molecular Transport's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Applied Molecular Transport's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Molecular Transport's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Molecular Transport's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Applied Molecular Transport's ROC (Joel Greenblatt) % falls into.



Applied Molecular Transport ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.86) - (1.809 + 0 + 0.549)
=-1.498

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.716) - (1.55 + 0 + 0.872)
=-1.706

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Applied Molecular Transport for the quarter that ended in Sep. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-29.028/( ( (1.516 + max(-1.498, 0)) + (1.196 + max(-1.706, 0)) )/ 2 )
=-29.028/( ( 1.516 + 1.196 )/ 2 )
=-29.028/1.356
=-2,140.71 %

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied Molecular Transport  (NAS:AMTI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Applied Molecular Transport ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Applied Molecular Transport's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Molecular Transport (Applied Molecular Transport) Business Description

Traded in Other Exchanges
N/A
Address
450 East Jamie Court, South San Francisco, CA, USA, 94080
Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.
Executives
Shawn Cross officer: Chief Financial Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Mahmood Tahir Ph.d. director, officer: Chief Executive Officer 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Brandon Hants officer: VP, Finance & Bus. Ops. 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Douglas A. Rich officer: Chief Technical Officer C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Bittoo Kanwar officer: Chief Medical Officer 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Mrsny Randall Ph.d. director, officer: Chief Scientific Officer 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Aaron Vandevender director 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
David Lamond director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Epiq Capital Group, Llc other: Managing member of 10% owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Chad Boeding other: CEO of Managing Member ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Charlene A. Banard director C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
John W Smither director C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Epq Llc Amt Ps other: Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Amtc Ps other: Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Amtb Ps 10 percent owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521

Applied Molecular Transport (Applied Molecular Transport) Headlines

From GuruFocus

Applied Molecular Transport Provides Strategy Update

By GuruFocusNews GuruFocusNews 07-07-2022